References
- Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet. 2018;391(10129):1524–1537.
- Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
- Matasar MJ, Dacosta Byfield S, Blauer-Peterson C, et al. Real-world health care utilization and costs among patients newly initiating systemic therapy for chronic lymphocytic leukemia (CLL) in the United States. Blood. 2016;128(22): 5928.
- US Food and Drug Administration. Prescribing Information – CALQUENCE (acalabrutinib). Accesssed on April 17 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf.
- US Food and Drug Administration. Prescribing Information – IMBRUVICA (ibrutinib). Accesssed on April 17 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s029,210563s004lbl.pdf.
- US Food and Drug Administration. Prescribing Information – VENCLEXTA (venetoclax) (Revised 05/2019). Accesssed on April 17 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208573s011s014s015lbl.pdf.
- US Food and Drug Administration. Prescribing Information – ZYDELIG (idelalisib). Accesssed on April 17 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205858s013lbl.pdf.
- US Food and Drug Administration. Prescribing Information – GAZYVA (obinutuzumab). Accesssed on April 17 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125486s025lbl.pdf.
- US Food and Drug Administration. Prescribing Information – COPIKTRA (duvelisib). Accesssed on April 17 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211155s001lbl.pdf.
- Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–798.
- Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031–2042.
- US Food and Drug Administration. Prescribing Information – VENCLEXTA (venetoclax) (Revised 04/2016). Accesssed on April 17 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf.
- US Food and Drug Administration. Prescribing Information – VENCLEXTA (venetoclax) (Revised 06/2018). Accesssed on April 17 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208573s004s005lbl.pdf.
- Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75.
- Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–322.
- Rogers KA, Huang Y, Ruppert AS, et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood. 2018;132(15):1568–1572.
- Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–778.
- Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973–1980.
- Cramer P, von Tresckow J, Bahlo J, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215–1228.
- Fischer K, Al-Sawaf O, Fink AM, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702–2705.
- Flinn IW, Gribben JG, Dyer MJS, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019;133(26):2765–2775.
- de Vos S, Swinnen LJ, Wang D, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932–1938.
- Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269–277.
- Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
- Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095–2103.
- Tambaro FP, Wierda WG. Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol. 2020;7(2):e168–e176.
- Mato AR, Thompson M, Allan JN, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511–1517.
- Wierda WG, James DF, Ninomoto J, et al. Ibrutinib (Ibr) plus venetoclax (Ven) for first-line treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): results from the MRD cohort of the phase 2 CAPTIVATE study. Blood. 2019;134(Suppl 1):35–35.
- Aroke H, Cirincione A, Kogut S. Length of stay, hospitalization cost, and in-hospital mortality associated with tumor lysis syndrome among patients with chronic lymphocytic leukemia. Value in Health. 2018;21 (Suppl 1):S23–S24.
- Department of Health and Human Services. 45 CFR Subtitle A. Accesssed on January 7, 2021. Available from: https://www.govinfo.gov/content/pkg/CFR-2016-title45-vol1/pdf/CFR-2016-title45-vol1-part46.pdf.
- Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat – Simul Comput. 2009;38(6):1228–1234.
- Sullivan GM, Feinn R. Using effect size-or why the P value is not enough. J Graduate Med Educ. 2012;4(3):279–282.
- Wasserstein RL, Lazar NA. The ASA statement on p-values: context, process, and purpose. Am Statistician. 2016;70(2):129–133.
- Kabadi SM, Goyal RK, Nagar SP, et al. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States. Cancer Med. 2019;8(8):3803–3810.
- Koehler AB, Leung N, Call TG, et al. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leuk Lymphoma. 2020;61(10):2383–2388.
- Mato AR. Predicting TLS in venetoclax-treated CLL patients. Video J Hematol Oncol. 2019;25:4264–4270.
- Hampel PJ, Ding W, Call TG, et al. Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019;60(11):2712–2719.
- Anderson MA, Seymour JF. Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL? Leuk Lymphoma. 2020;61(10):2286–2283.